Compass Therapeutics share price logo

Compass Therapeutics

NASDAQ: CMPX

$0.86

-0.04

(-4.93%)

as on

Compass Therapeutics Stock Performance

as on October 3, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $0.83
    $0.98
    downward going graph

    3.12%

    Downside

    14.39%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.83
    $6.88
    downward going graph

    3.19%

    Downside

    703.08%

    Upside

    downward going graph

Compass Therapeutics share price movements today

Previous Close
$0.90
Open
$0.94
Volume
18.3M
Market Cap
$162.3M
Day's Low - High
$0.83 - $0.98
52 Week Low - High
$0.83 - $6.88

Compass Therapeutics Historical Returns

1 Month Return
-63.85 %
3 Month Return
-62.26 %
1 Year Return
-76.85 %
3 Year Return
-55.15 %
5 Year Return
0 %

Compass Therapeutics Stock Fundamentals & Key Indicators

Check Compass Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$162.3M

EPS (TTM)

-0.415

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.24

Industry PE ratio

-3.02

PEG Ratio

-0.25

EBITDA

-72.7M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-38.71%

Compass Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Compass Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Compass Therapeutics image
Compass Therapeutics
StrongBuy$162.3MNA-2.240.00%0.00%
Revolution Medicines image
Revolution Medicines
StrongBuy$44.1B609.62%-23.340.00%0.00%
Moderna image
Moderna
Neutral$75.4B-44.29%-24.08-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.5B180.98%30.1986.04%0.00%
Regeneron image
Regeneron
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for Compass Therapeutics Stock including INR - Dollar returns

The Compass Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Compass Therapeutics investment value today

Current value as on today

₹25,132

Returns

-₹74,868

(-74.87%)

Returns from Compass Therapeutics Stock

-₹76,846 (-76.85%)

Dollar Impact

₹1,978 (+1.98%)

Analyst Recommendation on Compass Therapeutics Stock

Based on 8 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 8 analysts, 75% of analysts recommend a 'BUY' rating for Compass Therapeutics. Average target price of $5.45

Compass Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Compass Therapeutics.

What analysts predicted

84.28%UPSIDE

Target Price

$5.45

Current Price

$0.8567

Analyzed by

8 Analysts

High

$12

Target

$5.45

Low

$1

Compass Therapeutics target price $5.45, a slight upside of 84.28% compared to current price of $0.8567. According to 8 analysts rating.

Indian Investors' Interest in Compass Therapeutics Stock

Search interest for Compass Therapeutics Stock has increased by 290% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:290% versus previous 30 day period

Compass Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
0
-
-
-
-
-
-
-
-
Gross Profit
-
0
-
-
-
-
-
0
0
-
Operating Income
-12
-15
-12
-16
-17
-21
-15
-17
-20
-26
EBITDA
-10
-12
-10
-14
-16
-19
-14
-15
-17
-25
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-10
-13
-10
-15
-16
-19
-14
-15
-18
-25
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-10
-13
-10
-15
-16
-19
-14
-15
-18
-25
Net Profit Margin
0.00%
100.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Compass Therapeutics Annual Profit & Loss

All numbers in Millions USD

Mar 2019
Mar 2020
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
0
-
Gross Profit
-1
-
-
-
-
-
0
-1
Operating Income
-38
-34
-27
-81
-41
-50
-56
-72
EBITDA
-35
-31
-25
-80
-34
-40
-47
-65
Interest Expense
0
1
0
0
2
-
-
-
Depreciation
1
2
2
1
1
1
1
1
Income Before Tax
-38
-34
-29
-82
-39
-42
-49
-66
Income Tax Expense
0
0
0
-
-
-
-
-
Net Income
-38
-34
-29
-82
-39
-42
-49
-66
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
100.00%
0.00%

Compass Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-10
-13
-10
-15
-16
-19
-14
-15
-18
-25
Operating Cash Flow
-13
-10
-11
-9
-13
-11
-10
-13
-17
-13
Investing Cash Flow
-4
6
29
15
11
-6
-95
-3
38
-4
Financing Cash Flow
17
0
0
0
0
-
129
1
3
-3
Change in Cash
0
-4
17
6
-2
-18
23
-15
24
-22

Compass Therapeutics Annual Cash Flow

All numbers in Millions USD

Mar 2019
Mar 2020
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-38
-34
-29
-82
-39
-42
-49
-66
Operating Cash Flow
-33
-31
-26
-19
-34
-40
-44
-49
Investing Cash Flow
-2
0
0
-1
-151
26
46
-93
Financing Cash Flow
64
0
48
118
75
2
17
129
Change in Cash
28
-32
21
97
-109
-10
19
-12

Global Institutional Holdings in Compass Therapeutics

Check out the Institutions with significant holdings in Compass Therapeutics.

Funds
Holdings
Vanguard
3.99%
VANGUARD INDEX FUNDS
3.28%
SPDR
3.05%
iShares
3.01%
James E. Flynn
2.00%
See all

Compass Therapeutics News & Key Events

  • img

    Today's Timeline - 23 September

    Wed, 04:20 PM

    -

    Guggenheim lowers Compass Therapeutics price target to $4, citing FDA's recommendation for a survival benefit trial for tovecimig.

Insights on Compass Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 643.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 84.3% return, outperforming this stock by 139.4%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, CMPX stock has moved down by -24.2%

About Compass Therapeutics

Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
OrganisationCompass Therapeutics
Headquarters80 Guest Street, Boston, MA, 02135, US
IndustryBiotechnology
CEOThomas J. Schuetz

Key Management of Compass Therapeutics

Name

Title

Mr. Barry Shin J.D., M.B.A.

Chief Financial Officer

Mr. Jonathan E. Anderman J.D.

Senior VP, General Counsel & Corporate Secretary

Anna Gifford

Senior Manager of Communications & Chief of Staff

Dr. James Kranz Ph.D.

VP and Head of Chemistry Manufacturing & Controls

Dr. Cynthia A. Sirard M.D., Ph.D.

Chief Medical Officer

Dr. Thomas J. Schuetz M.D., Ph.D.

CEO & Vice Chairman

Mr. Neil L. Lerner CPA

Senior VP & Chief Accounting Officer

Mr. Bing Gong Ph.D.

Chief Scientific Officer

Ms. Karin Herrera B.A.

Senior VP & Head of Clinical Operations

Mr. Arjun Prasad M.B.A., M.P.H.

Chief Commercial Officer

FAQs

What is Compass Therapeutics share price today?

Compass Therapeutics share price today is $0.86 as on at the close of the market. Compass Therapeutics share today touched a day high of $0.98 and a low of $0.83.

What is the 52 week high and 52 week low for Compass Therapeutics share?

Compass Therapeutics share touched a 52 week high of $6.88 on and a 52 week low of $0.83 on . Compass Therapeutics stock price today i.e. is closed at $0.86,which is 87.55% down from its 52 week high and 3.29% up from its 52 week low.

What is Compass Therapeutics's market capitalisation today?

Compass Therapeutics market capitalisation is $0.00T as on .

How to invest in Compass Therapeutics Stock (CMPX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Compass Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Compass Therapeutics Stock (CMPX) from India?

Indian investors can start investing in Compass Therapeutics (CMPX) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Compass Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Compass Therapeutics share’s latest price of $0.86 as on October 3, 2026 at 8:45 am IST, you will get 11.6727 shares of Compass Therapeutics. Learn more about fractional shares .